Insiders · VRDN

VRDN insider transactions

Viridian Therapeutics Inc. (VRDN) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for VRDN

• 59d
  Amendment: Chief Financial Officer Harmon Seth covered exercise/tax liability with 2,031 shares, decreasing direct ownership by 21% to 7,850 units (SEC Form 4)

  4/A - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 59d
  Amendment: Chief Operating Officer Beetham Thomas W. covered exercise/tax liability with 3,048 shares, decreasing direct ownership by 19% to 13,361 units (SEC Form 4)

  4/A - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 59d
  Amendment: Chief Legal Officer Tousignant Jennifer covered exercise/tax liability with 1,675 shares, decreasing direct ownership by 32% to 3,494 units (SEC Form 4)

  4/A - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 59d
  Amendment: President and CEO Mahoney Stephen F. covered exercise/tax liability with 7,408 shares, decreasing direct ownership by 18% to 33,349 units (SEC Form 4)

  4/A - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 64d
  Chief Legal Officer Tousignant Jennifer converted options into 5,169 shares and covered exercise/tax liability with 1,724 shares (SEC Form 4)

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 64d
  Chief Financial Officer Harmon Seth covered exercise/tax liability with 2,091 shares and converted options into 6,267 shares, increasing direct ownership by 116% to 7,790 units (SEC Form 4)

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 64d
  Amendment: SEC Form 4 filed by Chief Financial Officer Harmon Seth

  4/A - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 64d
  Amendment: SEC Form 4 filed by Chief Legal Officer Tousignant Jennifer

  4/A - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 64d
  Chief Operating Officer Beetham Thomas W. converted options into 9,409 shares and covered exercise/tax liability with 3,138 shares, increasing direct ownership by 90% to 13,271 units (SEC Form 4)

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 64d
  President and CEO Mahoney Stephen F. converted options into 18,357 shares and covered exercise/tax liability with 7,627 shares, increasing direct ownership by 48% to 33,130 units (SEC Form 4)

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 64d
  SEC Form 4 filed by Chief Medical Officer Tripuraneni Radhika

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 125d
  Chief Legal Officer Tousignant Jennifer sold $70,796 worth of shares (2,272 units at $31.16), closing all direct ownership in the company (SEC Form 4)

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 192d
  Director Fairmount Funds Management Llc bought $9,999,990 worth of shares (454,545 units at $22.00) (SEC Form 4)

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 309d
  SEC Form 4 filed by Director Cain Christopher W.

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 309d
  SEC Form 4 filed by Director Kiselak Tomas

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 309d
  SEC Form 4 filed by Director Morris Arlene

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 309d
  SEC Form 4 filed by Director Ajer Jeffrey Robert

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 309d
  SEC Form 4 filed by Director Gheuens Sarah

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 309d
  SEC Form 4 filed by Director Moses Jennifer K.

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 330d
  Director Fairmount Funds Management Llc exercised 14,100 shares at a strike of $11.80 (SEC Form 4)

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 393d
  SEC Form 4 filed by Director Ajer Jeffrey Robert

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 393d
  SEC Form 3 filed by new insider Ajer Jeffrey Robert

  3 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 421d
  SEC Form 4 filed by Chief Medical Officer Tripuraneni Radhika

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 421d
  SEC Form 3 filed by new insider Tripuraneni Radhika

  3 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 421d
  SEC Form 4 filed by Director Cain Christopher W.

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 421d
  SEC Form 3 filed by new insider Cain Christopher W.

  3 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 429d
  SEC Form 4 filed by Chief Legal Officer Tousignant Jennifer

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 429d
  SEC Form 4 filed by President and CEO Mahoney Stephen F.

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 429d
  SEC Form 4 filed by Chief Operating Officer Beetham Thomas W.

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 429d
  SEC Form 4 filed by Chief Financial Officer Harmon Seth

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 584d
  Chief Operating Officer Beetham Thomas W. bought $117,050 worth of shares (5,000 units at $23.41), increasing direct ownership by 500% to 6,000 units (SEC Form 4)

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 584d
  President and CEO Mahoney Stephen F. bought $499,262 worth of shares (21,400 units at $23.33) (SEC Form 4)

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 597d
  Director Fairmount Funds Management Llc bought $30,000,000 worth of shares (1,600,000 units at $18.75) (SEC Form 4)

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 678d
  SEC Form 4 filed by Director Gheuens Sarah

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 678d
  SEC Form 4 filed by Director Harwin Peter Evan

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 678d
  SEC Form 4 filed by Director Moses Jennifer K.

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 678d
  SEC Form 4 filed by Director Morris Arlene

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 766d
  Fairmount Funds Management Llc disposed of 5,859 shares and acquired 5,859 shares (SEC Form 4)

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 813d
  SEC Form 3 filed by new insider Tousignant Jennifer

  3 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 813d
  SEC Form 4 filed by Tousignant Jennifer

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 820d
  SEC Form 4 filed by Ciulla Thomas

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 834d
  Fairmount Funds Management Llc bought $9,999,990 worth of shares (476,190 units at $21.00) (SEC Form 4)

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 846d
  New insider Ciulla Thomas claimed ownership of 762 shares (SEC Form 3)

  3 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 906d
  SEC Form 4 filed by Harmon Seth

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 918d
  SEC Form 4 filed by Fairmount Funds Management Llc

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 918d
  SEC Form 3 filed by new insider Beetham Thomas W.

  3 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 918d
  SEC Form 4 filed by Beetham Thomas W.

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 918d
  SEC Form 4 filed by Mahoney Stephen F.

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 918d
  SEC Form 3 filed by new insider Mahoney Stephen F.

  3 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 955d
  SEC Form 4 filed by Gheuens Sarah

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 955d
  SEC Form 3 filed by new insider Gheuens Sarah

  3 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 961d
  SEC Form 3 filed by new insider Harmon Seth

  3 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1052d
  SEC Form 4 filed by Meisner Lara

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1056d
  SEC Form 4 filed by Harwin Peter Evan

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1056d
  SEC Form 4 filed by Kiselak Tomas

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1056d
  SEC Form 4 filed by Moses Jennifer K.

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1056d
  SEC Form 4 filed by Morris Arlene

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1066d
  SEC Form 4 filed by Meisner Lara

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1121d
  SEC Form 4 filed by Myers Scott Dunseth

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
• 1151d
  SEC Form 4: Myers Scott Dunseth bought $160,324 worth of shares (5,500 units at $29.15), increasing direct ownership by 2% to 255,500 units

  4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)